NeuroSense Therapeutics
NRSNNeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company based in Israel. The company's primary business focus is the discovery and development of therapeutics for patients suffering from neurodegenerative diseases. Its lead program targets Amyotrophic Lateral Sclerosis (ALS), a progressive and fatal motor neuron disease. The company's strategy involves targeting multiple key disease mechanisms simultaneously, such as neuroinflammation and iron-mediated cell death, which are implicated in ALS pathology. NeuroSense's lead drug candidate, PrimeC, is an orally administered fixed-dose combination therapy currently being evaluated in a Phase IIb clinical trial (PARADIGM) for ALS. The company is also exploring the therapeutic potential of PrimeC in other neurodegenerative conditions, including Alzheimer's disease. As a publicly traded entity, NeuroSense Therapeutics operates within the biotechnology and neuroscience sectors. The company collaborates with academic and industry partners to advance its pipeline and employs biomarker-based analyses to assess target engagement and treatment efficacy in its clinical programs.
NRSN · Stock Price
Historical price data
About
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company based in Israel. The company's primary business focus is the discovery and development of therapeutics for patients suffering from neurodegenerative diseases. Its lead program targets Amyotrophic Lateral Sclerosis (ALS), a progressive and fatal motor neuron disease. The company's strategy involves targeting multiple key disease mechanisms simultaneously, such as neuroinflammation and iron-mediated cell death, which are implicated in ALS pathology. NeuroSense's lead drug candidate, PrimeC, is an orally administered fixed-dose combination therapy currently being evaluated in a Phase IIb clinical trial (PARADIGM) for ALS. The company is also exploring the therapeutic potential of PrimeC in other neurodegenerative conditions, including Alzheimer's disease. As a publicly traded entity, NeuroSense Therapeutics operates within the biotechnology and neuroscience sectors. The company collaborates with academic and industry partners to advance its pipeline and employs biomarker-based analyses to assess target engagement and treatment efficacy in its clinical programs.